Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.

Date publication

novembre 2025

Journal

The Lancet. Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Pr BOUCHE Olivier , Pr GHIRINGHELLI François , Dr VERNEREY Dewi , Dr VIENOT Angélique , Dr KIM Stephano , Dr BOUSTANI Jihane , Mme MEURISSE Aurélia

Tous les auteurs :
Kim S, Boustani J, Iseas S, Vernerey D, Evesque L, Quero L, Ghiringhelli F, Coutzac C, Bouché O, Chibaudel B, Vernet C, Vienot A, Tougeron D, Nguyen T, Rebucci-Peixoto M, Meurisse A, Chennoufi S, Maritaz C, Borg C,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41202834

Résumé

The standard of care for patients with locally advanced squamous cell anal carcinoma (SCAC) is concurrent chemoradiotherapy; however, recurrence rates are almost 40% and severe toxic effects include treatment-related colostomy. Anti-PD-1 agents are effective in those with treatment-naive recurrent or metastatic SCAC. We aimed to evaluate the activity and safety of the PD-1 inhibitor ezabenlimab plus modified docetaxel, cisplatin, and fluorouracil (mDCF) in patients with treatment-naive stage 3 SCAC.

Référence

Lancet Oncol. 2025 11 4;: